Myomo Inc (DE:0M61)
XASE:0M61
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.Company Guidance
Modest Revenue Growth
Q1 2026 revenue of $10.1M, up 3% year-over-year; company reiterated full-year revenue guidance of $43M–$46M.
Higher Average Selling Price (ASP)
ASP rose to $58,800 in Q1, up 9% year-over-year driven by Medicare Part B/MA fee updates and favorable channel mix (higher international and MA revenues). Management notes a longer-term ASP assumption nearer ~$55k.
Improved Gross Margin and Operating Efficiency
Gross margin expanded 100 basis points to 68.2% from 67.2% a year ago; operating expenses fell 1% year-over-year to $10.1M, contributing to a narrower operating loss of $3.2M (from $3.5M prior-year).
Adjusted EBITDA Improvement
Adjusted EBITDA improved from a negative $2.8M to a negative $2.3M (roughly a $0.5M improvement, ~18–20% improvement year-over-year).
Shift Toward Recurring Patient Sources
Recurring patient sources represented 49% of Q1 revenue, up from 25% in the prior year, reflecting traction from MyoConnect, rehab referrals and O&P partnerships.
Strong International and O&P Growth
International revenue reached a Q1 record of approximately $2.0M and rose 53% year-over-year; U.S. O&P channel revenue grew 79% year-over-year; Germany now has 100+ O&P practices and further international expansion planned.
Healthy Pipeline and Fulfillment Velocity
Pipeline reached 1,680 patients (up 10% sequentially and 13% year-over-year); Q1 added 723 patients (up 7% sequentially); intra-quarter fulfillments comprised 62% of revenue units versus 45% a year ago; backlog exited quarter at 226 patients.
Product and Clinical Advances
Launched a new mobile app in March (reduces material costs by ~10%, benefit to gross margin expected beginning Q2); University of Utah randomized control trial underway (18 of 50 enrolled); development of MyoPro 3 progressing.
Expanded Market Access via Payer Contracts
Signed a national arrangement with Elevance (Anthem) covering plans in 27 states; covered lives increased from 9M to 158M since April 2024, producing higher authorization rates for in-network plans.
Improved Cash and Lower Cash Burn
Cash, cash equivalents and short-term investments of $15.7M as of 03/31/2026; cash use in Q1 was $2.7M versus $3.2M in Q1 2025.
DE:0M61 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:0M61 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €0.74 | €0.69 | -6.11% |
Mar 09, 2026 | €0.65 | €0.58 | -10.08% |
Nov 10, 2025 | €0.77 | €0.74 | -4.02% |
Aug 11, 2025 | €1.54 | €0.70 | -54.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Myomo Inc (DE:0M61) report earnings?
Myomo Inc (DE:0M61) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Myomo Inc (DE:0M61) earnings time?
Myomo Inc (DE:0M61) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Myomo Inc stock?
The P/E ratio of Myomo is N/A.
What is DE:0M61 EPS forecast?
DE:0M61 EPS forecast for the fiscal quarter 2026 (Q2) is -0.08.
